$104.71
Value $182B
ABT and KNSA stock compared: price, dividend, valuation and results, from SEC filings.
$104.71
Value $182B
$95.11
Value $7.1B
Abbott Laboratories (ABT) has a market value of $182B and Kiniksa Pharmaceuticals International (KNSA) $7.1B. Over the last year, with dividends, ABT moved -17.8% and KNSA +135.9%. The P/E is 38.7 for ABT and 64.4 for KNSA. Dividend yield: ABT 2.41%, KNSA none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ABT$182B
KNSA$7.1B
ABT is 26 times KNSA
Revenue, 12 months
ABT$48.2B
KNSA$946M
ABT is 51 times KNSA
Net income, 12 months
ABT$4.7B
KNSA$110M
ABT is 43 times KNSA
Operating margin
ABT13.8%
KNSA13.8%
About the same
ROIC
ABT6.3%
KNSA15.9%
9.6 points apart
P/E
ABT38.7
KNSA64.4
KNSA is 1.7 times ABT
Dividend yield
ABT2.4%
KNSA0.0%
2.4 points apart
5-year return
ABT-11.6%
KNSA+638.4%
650.0 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ABT-11.6%
KNSA+638.4%
| Period | ABTWith dividends | KNSAWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | -17.8%Price -19.8% | +135.9%Price +135.9% |
| 3 years since November 17, 2023 | +12.0%+3.9% a yearPrice +5.2% | +505.4%+82.3% a yearPrice +505.4% |
| 5 years since November 16, 2021 | -11.6%-2.4% a yearPrice -20.0% | +638.4%+49.2% a yearPrice +638.4% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ABTAbbott LaboratoriesKNSAKiniksa Pharmaceuticals International
| Price | $104.71 | $95.11 |
|---|---|---|
| Market value | $182B | $7.1B |
| Enterprise value (EV) | $209B | $6.5B |
| P/E | 38.7 | 64.4 |
| P/E, 5-year median | 33.7 | 55.0 |
| P/B | 3.6 | 9.9 |
| EV/EBIT | 31.4 | 49.7 |
| Free cash flow yield | 3.7% | 2.8% |
| Revenue, 12 months | $48.2B | $946M |
|---|---|---|
| Net income, 12 months | $4.7B | $110M |
| Free cash flow, 12 months | $6.8B | $197M |
| Earnings per share, 12 months | $2.69 | $1.31 |
| Revenue growth, year on year | 5.7% | 60.1% |
| Revenue growth a year, past | +5.1%over 5 years | +104.8%over 4 years |
| EPS growth a year, past | +8.3%over 5 years | – |
| Gross margin | 56.9% | 90.2% |
|---|---|---|
| Operating margin | 13.8% | 13.8% |
| Net margin | 9.8% | 11.6% |
| ROIC | 6.3% | 15.9% |
| ROE | 9.1% | 17.8% |
| Cash | $4.3B | $569M |
|---|---|---|
| Total debt | $31.2B | $7.9M |
| Net debt / EBITDA | 3.3 | -4.3 |
| Interest cover | 6.7× | – |
| Dividend yield | 2.4% | – |
|---|---|---|
| Dividend per share, 12 months | $2.52 | – |
| Dividend growth a year, past | +10.4%over 5 years | – |
| Buyback yield | 0.5% | – |
| Shareholder yield | 2.9% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Abbott Laboratories ($182B) is about 25.8 times Kiniksa Pharmaceuticals International ($7.1B), at today's prices.
Since November 16, 2021, ABT's price moved -20.0% and KNSA's +638.4%. With dividends: ABT -11.6% (-2.4% a year), KNSA +638.4% (+49.2% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.41% for Abbott Laboratories and none for Kiniksa Pharmaceuticals International. Over the last twelve months they paid $2.52 and – per share.
At today's price, the P/E is 38.7 for ABT and 64.4 for KNSA. The median of the last five years was 33.7 and 55.0, which shows where each stands against its own past.
Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and 11.6% for Kiniksa Pharmaceuticals International, and the operating margin 13.8% and 13.8%. Revenue was $48.2B and $946M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.